Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. is a development-stage medical technology company developing blood purification and dialysis-like therapies for cardiovascular disease, cancer and severe inflammatory conditions. News about SIGY commonly covers Sigyn Therapy, Sigyn CardioDialysis, ImmunePrep, ChemoPrep and ChemoPure, including product-development presentations, annual-report references and shareholder communications.
Company updates also include capital-structure actions such as its completed reverse stock split and disclosures tied to OTCQB trading, SEC reporting and the development pathway for its therapeutic candidates.
Sigyn Therapeutics (OTCQB: SIGY) will present at LD Micro Main Event XIX on Tuesday, October 21, 2025 at 4:00 PM PT at the Hotel del Coronado in San Diego.
Jim Joyce, CEO and inventor, will deliver the company presentation. The three-day conference runs October 19–21, 2025, features about 120 companies presenting in half-hour slots, and includes one-on-one investor meetings and a closing reception.
Investors can attend in person or register to watch the virtual presentation.
Sigyn Therapeutics (OTCQB: SIGY) will present at LD Micro Main Event XIX on Tuesday, October 21, 2025 at 4:00 PM PT at the Hotel del Coronado in San Diego. CEO and inventor Jim Joyce will deliver the presentation and the company will be available for investor meetings during the three-day event running October 19–21, 2025.
The conference features ~120 companies presenting in half-hour slots and includes keynotes, company presentations, one-on-one investor meetings, and a closing reception. A virtual registration option is available for the presentation.
Sigyn Therapeutics (OTCQB:SIGY) has been featured in a new research report by Goldman Small Cap Research, highlighting the company's development of next-generation blood purification therapies. The company's flagship product, Sigyn Therapy™, is a first-in-class device targeting severe inflammatory disorders, primarily sepsis and end stage renal disease (ESRD).
The device has demonstrated capability to reduce bacterial toxins, inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. Additionally, Sigyn is developing medical devices to enhance cancer drug treatment effectiveness.
According to the research report, Sigyn plans to submit multiple Breakthrough Device submissions this year and expects to commence an ESRD feasibility study within the next 12 months. The study could yield data within 6 months of completion. Goldman Small Cap Research has issued a price target for SIGY, suggesting the company is currently undervalued compared to peers.
Sigyn Therapeutics (OTCQB:SIGY), a developer of next-generation blood purification therapies, is the subject of a new research report by Goldman Small Cap Research. The company's flagship product, Sigyn Therapy™, is a first-in-class device targeting severe inflammatory disorders, primarily sepsis and end-stage renal disease (ESRD).
The device has demonstrated effectiveness in reducing bacterial toxins, inflammatory cytokines, hepatic toxins, and infectious viral pathogens from human blood plasma. Additionally, Sigyn is developing medical devices to enhance cancer drug treatment effectiveness.
According to the research report, Sigyn plans to submit multiple Breakthrough Device submissions this year and expects to commence an ESRD feasibility study within the next 12 months. Data from this trial could be available within 6 months of study completion.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.